TrialBlood2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
John C Byrd et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
128 papers cite itlatest 60 shown
this paperpooled ittrialcites it
TrialBlood2019
John C Byrd et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.